Amgen (AMGN) recently released robust third-quarter results, driving its stock price to a one-year high. Thanks to double-digit year-over-year revenue growth and multiple indicators exceeding market expectations, the company’s management subsequently raised its full-year performance guidance. Following the earnings release, Deutsche Bank analyst James Shin increased Amgen’s target stock price from $280 to $285. Although he maintained a “hold” rating, this adjustment still contributed to a nearly 5% single-day stock price increase, with the closing price approaching a one-year high.
In response to challenges posed by the patent expirations of some core drugs, Amgen is actively planning for the future by advancing innovative drug development. Among these efforts, the weight management drug MariTide has performed particularly well, demonstrating sustained weight loss effects in clinical trials. With dosing required only once a month, it offers greater convenience compared to existing weekly injection therapies. Some predictions suggest that the drug could achieve annual sales of $3.7 billion by 2030. Additionally, Amgen’s R&D pipeline includes several drugs with significant market potential. For example, bemarituzumab, a treatment for gastric cancer, has achieved positive results in Phase III clinical trials and is expected to gain approval in 2027. Recently launched drugs such as the lung cancer treatment Imdelltra and the asthma drug Tezspire are also expected to gradually contribute to revenue, forming a relay of products.
Amgen has long adhered to a stable shareholder return policy, consistently increasing dividends since 2011, with a cumulative dividend growth of over 200% in the past decade. The company’s current dividend yield stands at 3.5%, significantly higher than the S&P 500 average, while its payout ratio remains at a healthy 46.5%. This demonstrates the company’s ability to sustain dividend payments and potentially increase them further. In terms of valuation, Amgen’s forward P/E ratio is 12.6x, lower than the industry average of 16.4x, indicating that its stock price has already factored in risks such as patent expirations to some extent. For long-term investors, the current valuation level, combined with the company’s solid pipeline and prudent financial policies, presents an attractive investment opportunity.
